Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Xenon Pharmaceuticals (XENE) Reports Q1 Loss of $0.42, Revenues Miss
May 11, 2021 4:32 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.42), versus ($0.22) reported last year. Revenue for the quarter came in at $4.36 million versus the consensus estimate of $5.15 million.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make excellent progress across both our proprietary and partnered programs. In particular, I... More
